Lunai Bioworks Inc. (LNAI) Stock Price & Analysis
Lunai Bioworks Inc. (LNAI) rose 1.70% to USD 2.39 as of September 8, 2026 at 10:54 UTC, according to Nexqual real-time market data.
LNAI last closed at USD 2.35; the session ranged USD 2.3–2.4 on volume of 12,632 shares. Market capitalization is $10.84M, with a 52-week range of USD 1.21–17.84 (NCM). Source: Nexqual, September 8, 2026 at 10:54 UTC.
Key Statistics (as of September 8, 2026 at 10:54 UTC)
| Price | USD 2.39 |
|---|---|
| Change | ▲ 1.70% (up) |
| Previous Close | USD 2.35 |
| Open | USD 2.35 |
| Day Range | USD 2.3 – 2.4 |
| 52-Week Range | USD 1.21 – 17.84 |
| Volume | 12,632 shares |
| Market Cap | $10.84M |
| Exchange | NCM |
Technical Analysis (LNAI)
Nexqual's technical model rates LNAI "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 10:54 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.76 (neutral) |
| vs SMA50 | Below (USD 2.52) |
| MACD | -0.03 (negative) |
Analyst Ratings (LNAI)
Wall Street analysts rate LNAI "None", per Nexqual as of September 8, 2026 at 10:54 UTC.
| Consensus Rating | None |
|---|
Earnings (LNAI)
| Next Earnings Date | 2026-09-28 |
|---|
Source: Nexqual, September 8, 2026 at 10:54 UTC.
Financials & Fundamentals (LNAI)
| Total Revenue | $20,942 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -6815.30% |
| Profit Margin | +0.00% |
| ROE | -325.46% |
| Current Ratio | 0.19 |
| Total Cash | $3.16M |
| Total Debt | $1.41M |
| Free Cash Flow | $-6.96M |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
Financial Health Score (LNAI)
Nexqual rates Lunai Bioworks Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 10:54 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -325%, ROA -9.6% |
Ownership (LNAI)
| Insider Ownership | +40.72% |
|---|---|
| Institutional Ownership | +3.53% |
| Shares Outstanding | 4.53M |
| Float | 2.92M |
| Short % of Float | +3.94% |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
Leadership (LNAI)
Lunai Bioworks Inc. is led by David H. Weinstein (age 64), CEO & Director, per Nexqual as of September 8, 2026 at 10:54 UTC.
| CEO & Director | David H. Weinstein (age 64) |
|---|---|
| Chief Financial Officer | Nathen Fuentes (age 42) |
Major Backers & Investors (LNAI)
Notable institutional backers of Lunai Bioworks Inc. include Ground Swell Capital, LLC, Jane Street Group, LLC, Fidelity, according to Nexqual as of September 8, 2026 at 10:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ground Swell Capital, LLC | 1.17% |
| Jane Street Group, LLC | 0.52% |
| Fidelity | 0.47% |
| Virtu Financial LLC | 0.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.81% |
| Geode Capital | 0.53% |
| BlackRock | 0.35% |
Source: Nexqual, September 8, 2026 at 10:54 UTC.
From Lunai Bioworks Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)
Key Strengths & Strategy (as disclosed to the SEC)
- Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands.
- It operates through three segments, RENB, BioSymetrics, and RENC.
- The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
- It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIYA | Baiya International Group Inc. | USD 2.26 | ▲ 3.2% |
| AZI | Autozi Internet Technology (Glo | USD 1.24 | ▼ 1.59% |
| PAVS | Paranovus Entertainment Technol | USD 4.7 | ▼ 4.06% |
| PFSA | Profusa, Inc. | USD 2.72 | ▲ 1.87% |
| MASK | 3 E Network Technology Group Lt | USD 1.31 | ▼ 5.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:54 UTC. This page is informational and not investment advice.